In 2012, five pharmaceutical companies paid almost $5.5 billion to resolve allegations by the US Department of Justice for employing fraudulent marketing practices and off-label promotion of medicines. Here is a brief summary of the companies and fines:

Author:

Adrienne is currently completing her J.D. (2019) at Osgoode Hall Law School. She received her M.A. (2012) and Ph.D. (2016) in Health Policy & Equity with a focus on pharmaceutical policy, regulation, and patient safety.